2014, Number 3
<< Back Next >>
Rev Med Inst Mex Seguro Soc 2014; 52 (3)
Clinical analysis of 200 cases of idiopathic thrombocytopenic purpura
García-Stivalet LA, Muñoz-Flores A, Montiel-Jarquín ÁJ, Barragán-Hervella RG, Bejarano-Huertas R, García-Carrasco M, López-Colombo A
Language: Spanish
References: 15
Page: 322-325
PDF size: 113.90 Kb.
ABSTRACT
Background: Idiopathic thrombocytopenic purpura is characterized
by extravasation of blood into the subcutaneous tissue, mucous membranes
or skin; it generates bleeding manifestations as ecchymotic
lesions, petechiae of sudden onset, epistaxis, bleeding from the gums,
and serious complications such as intracranial hemorrhage. This condition
is due to a platelet destruction mediated by antibodies directed
against the surface of the platelets. The objective is to present the clinical
characteristics of patients with idiopathic thrombocytopenic purpura in a
third level medical facility in Puebla, México.
Methods: A descriptive study, which included 200 patients from the
Hematology Service, was carried out. All patients included had the diagnosis
of idiopathic thrombocytopenic purpura. We studied their clinical
manifestations, type of diagnosis, as well as medical and/or surgical
treatment. The statiscal analysis was made using descriptive measures.
Results: The entire sample (200 patients) had idiopathic thrombocytopenic
purpura as a diagnosis established, 57 % had ecchymoses, 42 %
petechiae, 23 % bleeding from the gums, 31.5 % epistaxis, 6.5 % abnormal
uterine bleeding, 11 % malaise, 7.0 % hemorrhage, 0.5 % pruritus,
0.5 % seizures, 8 % two or more signs and symptoms and 73 % was
asymptomatic when the diagnosis was established.
Conclusions: Symptoms of idiopathic thrombocytopenic purpura are
varied, a large percentage of patients can be processed unnoticed. The
results described were similar to those reported in the literature.
REFERENCES
Khalafallah A, Rahman Z, Ogden K, Hannan T. Successful treatment with thrombopoietin receptor agonist in avoiding splenectomy for patients with chronic refractory immune thrombocytopenia. Mediterr J Hematol Infect Dis. 2012;4(1):230-6.
Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther M. The American Society of Hematology 2011 Evidence-Based Practice Guideline for Immune Thrombocytopenia. Blood. 2011;117(16): 4190-207.
Howard A, Pullarkat V. Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics. Am Soc Hematol. 2011;2011(1): 384-90.
McCare K. Immune thrombocytopenia: No longer Idiopathic. Cleve Clinic J Med. 2011;78(6):358-73.
Lichtman M, Beutler E, Kipps T, Williams W. Manual de hematología de Williams. Madrid; España: Marbán. p. 396-414.
Martínez-Murillo C, Actualización en el diagnóstico y tratamiento de la púrpura trombocitopénica idiopática autoinmune. Rev Hematol. 2006;7(1):7-16.
Ochoa R, Lozada O, Bastidas G. Púrpura trombocitopénica inmune en la infancia. 20 años de experiencia: 1985-2005. Estado Cojedes-Venezuela. Arch Venez Puer Ped. 2008;71(4):105-11.
Flores-López A, Orna-Montero E. Tratamiento de la púrpura trombocitopénica inmune del adulto. Rev Hematol Mex. 2010;11(2):95-100.
Zaja F, Baccarani M, Mazza P, Bhochia M, Gugliotta L, Zaccaria A, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010;115 (14):2755-62.
Sánchez-Pérez MA, Romero-Hernández T, Blanco- Benavides R. Incidencia de esplenectomías en un hospital de tercer nivel de atención. Rev Med Inst Mex Seguro Soc. 2008;46(4):435-8.
Kurter D, Phil MD, Rummel M, Boccia R, Macik G, Pabinger I, et al. Romiplastim or standard of care in patients with immune thrombocytopenic. New Engl J Med. 2010;363(20):1889-99.
Hernández-Galano G, Castro-Arenas R, Hernández- Cruz C, Pérez-Valiente D, Carnot-Uría J, Muñío- Perurena J, et al. Resultados terapéuticos de la púrpura trombocitopénica crónica. Rev Cubana Hematol Inmunol Hemoter. 2006;2(2):34-9.
Monteagudo E, Fernández R, Sastre A, Toll T, Llort A, Molina J, et al. Protocolo de estudio y tratamiento de la trombocitopenia inmune primaria (PTI-2010). An Pediatr (Barc). 2011;30(20):30.e1-8.
Sequeira-Rojas L. Púrpura trombocitopénica autoinmune (caso clínico y revisión bibliográfi ca). Rev Med Costa Rica. 2008;65(582)9-13.
Sarpatwari A, Bennett D, Logie J, Shukla A, Beach K, Newland A. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Hematologica. 2010;95(7):1167-75.